Treister Roi, Lodahl Mette, Lang Magdalena, Tworoger Shelley S, Sawilowsky Shlomo, Oaklander Anne Louise
Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
J Pain. 2017 May;18(5):556-563. doi: 10.1016/j.jpain.2016.12.014. Epub 2017 Jan 4.
Small-fiber polyneuropathy (SFPN) affects unmyelinated and thinly myelinated peripheral axons. Several questionnaires have been developed to assess polyneuropathy from diabetes or chemotherapy, but none for SFPN from other or unknown causes. A comprehensive survey could help clinicians diagnose and assess treatment responses, define prevalence natural history and cures, and identify research subjects. Thus, we developed the 1-page Small-Fiber Symptom Survey, using input from patients and 21 medical/scientific experts. Participants comprised consenting consecutive patients evaluated for SFPN at the Massachusetts General Hospital plus normal control subjects. Participants SFPN status was stratified on the basis of the results of their objective diagnostic tests (distal leg skin biopsy and autonomic function testing). We measured internal consistency, test retest reliability, convergent validity, and performed a receiver operating curve analysis. The 179 participants averaged 46.6 ± 15.6 years old; they were 73.2% female and 92.2% Caucasian. Eighty-five had confirmed SFPN, mostly idiopathic. Principal component analysis revealed 5 symptom clusters. The questionnaire had good internal consistency (Cronbach α = .893), excellent test retest reliability (r = .927, P < .001) and good to fair convergent validity. Participants with confirmed SFPN had more severe symptoms than others (P = .009). The Small-Fiber Symptom Survey has satisfactory psychometric properties, indicating potential future utility for surveying patient-reported symptoms of SFPN regardless of its cause.
This article reports the initial development and early psychometric validation of a new patient-reported outcome measure intended to capture the wide range of multisystem symptoms of SFPN. When further developed, it could potentially help clinicians diagnose and monitor patients, and help advance research.
小纤维多发性神经病(SFPN)会影响无髓鞘和薄髓鞘的外周轴突。已经开发了几种问卷来评估糖尿病或化疗引起的多发性神经病,但没有针对其他原因或不明原因引起的SFPN的问卷。全面的调查有助于临床医生诊断和评估治疗反应,确定患病率、自然病史和治愈率,并识别研究对象。因此,我们利用患者和21位医学/科学专家的意见,开发了1页的小纤维症状调查问卷。参与者包括在马萨诸塞州总医院接受SFPN评估的连续同意患者以及正常对照受试者。根据他们的客观诊断测试结果(小腿远端皮肤活检和自主神经功能测试)对参与者的SFPN状态进行分层。我们测量了内部一致性、重测信度、收敛效度,并进行了受试者工作特征曲线分析。179名参与者的平均年龄为46.6±15.6岁;女性占73.2%,白种人占92.2%。85人确诊为SFPN,大多数为特发性。主成分分析揭示了5个症状群。该问卷具有良好的内部一致性(Cronbach α = 0.893)、出色的重测信度(r = 0.927,P < 0.001)和良好至中等的收敛效度。确诊为SFPN的参与者比其他人有更严重的症状(P = 0.009)。小纤维症状调查问卷具有令人满意的心理测量特性,表明其未来有可能用于调查患者报告的SFPN症状,无论其病因如何。
本文报告了一种新的患者报告结局测量方法的初步开发和早期心理测量学验证,该方法旨在捕捉SFPN广泛的多系统症状。进一步开发后,它可能有助于临床医生诊断和监测患者,并推动研究进展。